Evaluación de parámetros de estrés oxidativo y actividades metabólicas de enfermeras trabajando en turnos diurnos y nocturnos

Se objetivó evaluar estrés oxidativo y actividades metabólicas de enfermeras en turnos diurnos y nocturnos. Participaron enfermeras de Unidad de Terapia Intensiva (UTI, n=70) y del servicio común (SC, n=70). Se obtuvieron muestras sanguíneas al inicio y al final de los turnos para medir parámetros de estrés oxidativo. Las actividades metabólicas también fueron analizadas utilizando brazaletes SenseWear. Los parámetros de estrés oxidativo aumentaron hacia el final de los turnos de todas las enfermeras SC y UTI, comparados con la medida de inicio. Los niveles de TAS, TOS y OSI no eran significativamente diferentes entre enfermeras SC y UTI al cierre de los turnos diurnos y nocturnos. Las actividades metabólicas de enfermeras SC y UTI se mostraron similares. Consecuentemente, los parámetros de estrés oxidativo y las actividades metabólicas de enfermeras SC y UTI no resultaron diferentes, y todas las enfermeras sufren efectos semejantes en sus turnos, tanto diurnos como nocturnos.O objetivo deste estudo foi avaliar o estresse oxidativo e as atividades metabólicas das enfermeiras em turnos diurnos e noturnos. Enfermeiras da Unidade de Tratamento Intensivo (UTI) (n=70) e do serviço comum (SC) (n=70) participaram do estudo. Logo no início e ao final dos turnos, amostras de sangue foram obtidas para medir parâmetros de estresse oxidativo. Atividades metabólicas também foram analisadas com o uso da braçadeira SenseWear. Parâmetros de estresse oxidativo aumentaram no fim dos turnos de todas as enfermeiras SC e UTI quando comparados ao início dos turnos. Comparados às enfermeiras SC, os níveis de TAS, TOS e OSI das enfermeiras de UTI não eram significativamente diferentes no final dos turnos diurnos e noturnos. Além disso, as atividades metabólicas das enfermeiras de SC e UTI se revelaram como sendo similares. Assim, os parâmetros de estresse oxidativo e as atividades metabólicas das enfermeiras SC e UTI não eram diferentes, e todas as enfermeiras sofrem efeitos semelhantes dos turnos, tanto no dia quanto na noite.The aim of this study was to evaluate the oxidative stress and metabolic activities of nurses working day and night shifts. Intensive care unit (ICU) (n=70) and ordinary service (OS) nurses (n=70) were enrolled in the study. Just before and the end of the shifts, blood samples were obtained to measure the participants' oxidative stress parameters. Metabolic activities were analyzed using the SenseWear Armband. Oxidative stress parameters were increased at the end of the shifts for all OS and ICU nurses compared to the beginning of the shifts. Compared to the OS nurses, the ICU nurses' TAS, TOS, and OSI levels were not significantly different at the end of the day and night shifts. The metabolic activities of the OS and ICU nurses were found to be similar. As a result, the OS and ICU nurses' oxidative stress parameters and metabolic activities were not different, and all of the nurses experienced similar effects from both the day and night shifts

Diyabetik Nefropatide SCUBE-1 ve sCD40L Seviyelerinin İncelenmesi

Amaç: Diyabetik nefropati ve aterosklerorik kalp hastalıkları arasında yakın bir ilişki mevcuttur. Biz de, ateroskleroz sürecinde rol oynadığı bilinen SCUBE-1 ve sCD40L’ın tip 2 diyabeti olan hastalarda, nefropatinin ilerlemesi ile birlikte nasıl değiştiğini araştırmayı amaçladık.Gereç ve Yöntemler: Otuz sağlıklı kişi (grup 1) ve 74 tip 2 diyabeti olan hasta (normal albuminüri grubu (grup 2, n=33), orta derece artmış albuminüri grubu (grup 3, n=22) ve şiddetli derecede artmış albuminüri grubu (grup 4, n=19) olarak üç gruba ayrıldı) çalışmaya dahil edildi. Plazma SCUBE-1 ve sCD40L seviyeleri, enzim-bağlı immunosorbent analiz tekniği kullanılarak ölçüldü.Bulgular: Ortalama SCUBE-1 seviyeleri grup 1 ve grup 2 ile karşılaştırıldığında, grup 4’te (sırasıyla p=0,005 ve p=0,014) ve grup 1 ve grup 2 ile karşılaştırıldığında grup 3’te (sırasıyla p=0,011 ve p=0,028) anlamlı olarak yüksekti. Ortalama sCD40L seviyeleri grup 4’te diğer üç gruptan (tüm p<0,001) ve grup 3’te ise grup 1 ve grup 2’den (sırasıyla p=0,001 ve p=0,016) anlamlı olarak yüksekti. Ayrıca SCUBE-1 seviyeleri total kolesterol seviyesi (r=0,220; p=0,025) ve trigliserit (r=0,194; p=0,049) ile pozitif yönlü koreleydi. Yanı sıra, sCD40L seviyesi ise sadece kreatinin seviyesi (r=0,297; p=0,002) ile pozitif yönlü koreleydi.Sonuç: SCUBE-1 ve sCD40L seviyeleri tip 2 diyabette nefropatinin progresyonu ile artmaktadır. Bu artış SCUBE-1 ve sCD40L’ın diyabetik nefropatiye bağlı ateroskleroz sürecinde anahtar rol oynuyor olabileceğini ve diyabetik nefropatinin bu parametrelerin seviyelerini etkiliyor olabileceğini düşündürmektedir

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

Yumuk, Perran Fulden/0000-0001-8650-299X; benekli, mustafa/0000-0003-3184-4946; Aykan, Nuri Faruk/0000-0002-5472-3218; Dane, Faysal/0000-0001-6584-902XWOS: 000527801000004PubMed: 32220908Objectives Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatment-refractory mCRC. Design Open-label, single-arm, phase IIIb study conducted between July 2013 and April 2015. Setting 11 tertiary centres in Turkey. Participants Eligible patients were adults with mCRC who had disease progression within 3 months after receiving their last dose of approved standard therapies and who had an Eastern Cooperative Oncology Group performance status = 3 TEAE. the most common grade >= 3 regorafenib-related TEAEs were hypophosphataemia (11%), fatigue (8%), hyperbilirubinaemia (6%), hand-foot skin reaction (5%), hypertension (5%), anorexia (5%) and increased alanine aminotransferase (5%). TEAEs led to dose reduction in 30% of patients. Regorafenib-related TEAEs led to treatment discontinuation in 17% of patients. Median PFS was 3.1 months (95% CI 2.9 to 3.8). Conclusion the regorafenib safety profile and PFS in REGARD were consistent with the results of previous trials of regorafenib in mCRC. Regorafenib is an option for patients in Turkey with treatment-refractory mCRC.BayerBayer AGThis work was supported by Bayer. Bayer provided the study medication and collaborated with the authors to design the study. Bayer worked with the investigators on the collection, analysis and interpretation of the data, and on the preparation of this report. the authors made the final decision to submit the article for publication

Urotensin-II and endothelin-I levels after contrast media administration in patients undergoing percutaneous coronary interventions

Background: Contrast induced kidney injury is an acute renal dysfunction that is secondary to the administration of radio contrast media. The purpose of this study was to evaluate the levels of urotensin-II (UT-II) and endothelin-I (ET-I) after contrast media administration in patients undergoing percutaneous coronary interventions. Materials and Methods: In this prospective cohort study, we evaluated 78 patients with coronary artery disease who were scheduled for and ultimately underwent percutaneous coronary interventions. As a contrast material, nonionic contrast media was used in various amounts (70-480 mL). Blood and urine samples were obtained to measure U-II, ET-I just before and at the twenty-fourth hour of percutaneous coronary interventions. Results: Compared to baseline, twenty-fourth hour creatinine levels were significantly increased ( P < 0.001). The twenty-fourth hour serum and urine levels of both UT-II and ET-I were also significantly increased compared to baseline ( P < 0.001 for all) and 24 th hour serum and urine UT-II (r = 0.322, P = 0.004; r = 0.302, P = 0.007 respectively), ET-I (r = 0.511, P < 0.001; r = 0.266, P = 0.019 respectively) levels were significantly correlated with the amount of contrast media. Conclusion: Our study indicates that; increased UT-II and ET-I levels seem to be a consequence of hazardous effects of contrast media on blood vessels and the kidney

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study

Objectives Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies in two randomised, phase III trials, but has not been evaluated in Turkey. REGARD evaluated the safety and efficacy of regorafenib in Turkish patients with treatment-refractory mCRC